- Home>
- Specialties>
- Cardiology>
- Stents
Search for Stents in Cardiology
Physician-authored summaries on the latest research on stents, editorials on stents, and perspectives on stents - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 357 results - Relevance
- Date
You searched for: stents in Cardiology
-
A Bioabsorbable Drug-Eluting Stent: 2-Year Data
- March 25, 2009
- Beat J. Meyer, MD
- Cardiology
Favorable findings from a feasibility study move us a step closer to reducing the thrombogenic risk of coronary stenting.- Reviewing:
- Serruys PW et al., Lancet 2009 Mar 14; 373:897. Colombo A and Sharp ASP., Lancet 2009 Mar 14; 373:869.
-
Bare-Metal and Drug-Eluting Stents: What’s the Bottom Line? Free
- June 24, 2008
- Howard C. Herrmann, MD
- Cardiology
Results of a retrospective study of Medicare patients suggest that, on balance, drug-eluting stents have improved outcomes.- Reviewing:
- Malenka DJ et al., JAMA 2008 Jun 25; 299:2868.
-
Drug-Eluting Stents: Is the Tide Turning?
- June 4, 2008
- Howard C. Herrmann, MD
- Cardiology
Registry data suggest that DES recipients may fare better than BMS recipients after all.- Reviewing:
- Hannan EL et al., J Am Coll Cardiol Intv 2008 Apr 1; 1:129. Grines CL et al., J Am Coll Cardiol Intv 2008 Apr 1; 1:136. Hannan EL et al., Circulation 2008 Apr 22; 117:2071. Mauri L and Normand SLT., Circulation 2008 Apr 22; 117:2047.
-
In Stent Recipients Taking Clopidogrel, High Platelet Reactivity Predicts Ischemic Events
- May 14, 2008
- Beat J. Meyer, MD
- Cardiology
In a prospective observational study, results of a point-of-care platelet-function assay correlated well with thrombotic risk after DES implantation.- Reviewing:
- Price MJ et al., Eur Heart J 2008 Apr; 29:992.
-
A New Drug-Eluting Stent on the Horizon
- May 7, 2008
- Howard C. Herrmann, MD
- Cardiology
Everolimus-eluting stents perform well in a comparison with paclitaxel-eluting stents, setting the stage for FDA approval and — more important — long-term outcome studies.- Reviewing:
- Stone GW et al., JAMA 2008 Apr 23; 299:1903. Patel MR and Holmes DR Jr., JAMA 2008 Apr 23; 299:1952.
-
Are High-Dose Tirofiban and Drug-Eluting Stents Best for STEMI?
- April 30, 2008
- Howard C. Herrmann, MD
- Cardiology
Results of a randomized study favor SES over BMS and show a high-dose bolus of tirofiban to be as good as abciximab.- Reviewing:
- Valgimigli M et al., JAMA 2008 Apr 16; 299:1788.
-
Are Sirolimus-Eluting and Paclitaxel-Eluting Stents Equivalent?
- January 30, 2008
- Howard C. Herrmann, MD
- Cardiology
Findings from a randomized study of actual clinical use suggest that they are, but the data are still inconclusive.- Reviewing:
- Galløe AM et al. for the SORT OUT II Investigators., JAMA 2008 Jan 30; 299:409. Mukherjee D and Moliterno DJ., JAMA 2008 Jan 30; 299:454.
-
Drug-Eluting Stents, Bare-Metal Stents, and Bypass Surgery Free
- January 23, 2008
- Howard C. Herrmann, MD
- Cardiology
Data from two studies suggest that when considering PCI, the setting matters more than the stent.- Reviewing:
- Marroquin OC et al., N Engl J Med 2008 Jan 24; 358:342. Hannan EL et al., N Engl J Med 2008 Jan 24; 358:331. Carrozza JP., N Engl J Med 2008 Jan 24; 358:405.
-
In Clinical Practice, Drug-Eluting Stents Outperform Bare-Metal Stents
- December 26, 2007
- Howard C. Herrmann, MD
- Cardiology
In a population-based cohort, DES resulted in fewer repeat revascularizations than BMS, with no difference in rates of death or MI at 1 year.- Reviewing:
- Abbott JD et al., J Am Coll Cardiol 2007 Nov 20; 50:2029. Büttner HJ and Neumann F-J., J Am Coll Cardiol 2007 Nov 20; 50:2037.
-
Stent Thrombosis and Restenosis After Bare-Metal Stenting
- December 12, 2007
- Howard C. Herrmann, MD
- Cardiology
A retrospective analysis of registry data suggests that BMS is no safer than DES for off-label use.- Reviewing:
- Doyle B et al., Circulation 2007 Nov 20; 116:2391. Williams DO and Abbott JD., Circulation 2007 Nov 20; 116:2363.
-
Sirolimus-Eluting Stents Outperform Bare-Metal Stents in Patients with Diabetes
- November 28, 2007
- Howard C. Herrmann, MD
- Cardiology
At 1 year of follow-up, results of the SCORPIUS study favored SES for both efficacy and safety.- Reviewing:
- Baumgart D et al., J Am Coll Cardiol 2007 Oct 23; 50:1627.
-
Drug-Eluting Stents vs. Bare-Metal Stents: The Ontario Experience Free
- October 3, 2007
- Howard C. Herrmann, MD
- Cardiology
Two-year results from a population-based, propensity-matched cohort study suggest that DES are more effective than BMS.- Reviewing:
- Tu JV et al., N Engl J Med 2007 Oct 4; 357:1393.
-
Another Meta-Analysis of Bare-Metal and Drug-Eluting Stents
- October 3, 2007
- Howard C. Herrmann, MD
- Cardiology
A study of outcomes helps to clarify the balance of the risks and benefits of the three most commonly used stent types.- Reviewing:
- Stettler C et al., Lancet 2007 Sep 15; 370:937.
-
Sirolimus-Eluting vs. Paclitaxel-Eluting Stents: A Meta-Analysis
- October 3, 2007
- Howard C. Herrmann, MD
- Cardiology
A study of 16 trials suggests that SES are superior to PES, but the whole picture is not yet clear.- Reviewing:
- Schömig A et al., J Am Coll Cardiol 2007 Oct 2; 50:1373. Kereiakes DJ., J Am Coll Cardiol 2007 Oct 2; 50:1381.
-
Increased Mortality with Sirolimus-Eluting Stents in Saphenous Vein Grafts? Free
- September 19, 2007
- Howard C. Herrmann, MD
- Cardiology
Post-hoc results from a small study may be cause for concern.- Reviewing:
- Vermeersch P et al., J Am Coll Cardiol 2007 Jul 17; 50:261. Ellis SG., J Am Coll Cardiol 2007 Jul 17; 50:268.
-
Bare-Metal or Drug-Eluting Stents for Coronary Artery Disease?
- August 29, 2007
- Howard C. Herrmann, MD
- Cardiology
In a large, observational study, DES use was not associated with higher rates of stent thrombosis, MI, or death, compared with BMS.- Reviewing:
- Jensen LO et al., J Am Coll Cardiol 2007 Jul 31; 50:463-70.
-
A Randomized Comparison of Drug-Eluting and Bare-Metal Stents in Left Main Lesions
- August 29, 2007
- Howard C. Herrmann, MD
- Cardiology
In a small trial, DES outperformed BMS in LMCA lesions, but how it compares with bypass surgery remains to be seen.- Reviewing:
- Erglis A et al., J Am Coll Cardiol 2007 Aug 7; 50:491-7. Stone GW et al., J Am Coll Cardiol 2007 Aug 7; 50:498-500.
-
Can Adjustment of Clopidogrel Dosing Reduce Ischemic Events After Stent Implantation?
- May 14, 2008
- Howard C. Herrmann, MD
- Cardiology
In a small but promising trial, adjusting the loading dose according to platelet reactivity improved clinical outcomes.- Reviewing:
- Bonello L et al., J Am Coll Cardiol 2008 Apr 8; 51:1404. Kleiman NS., J Am Coll Cardiol 2008 Apr 8; 51:1412.
-
Stents for Rescue Angioplasty After MI
- January 7, 2005
- Howard C. Herrmann, MD
- Cardiology
In a multicenter randomized study, researchers in Germany compared intracoronary stenting with conventional balloon angioplasty in 181 acute-MI patients who had been referred for rescue . . .- Reviewing:
- Schömig A et al. for the STOPAMI-4 Study Investigators., J Am Coll Cardiol 2004 Nov 16; 44:2073-9.
-
Prasugrel vs. Clopidogrel, Continued . . .
- April 23, 2008
- Beat J. Meyer, MD
- Cardiology
A subanalysis of TRITON-TIMI 38 suggests that prasugrel lowers stent thrombosis rates in high-risk ACS patients.- Reviewing:
- Wiviott SD et al. for the TRITON-TIMI 38 Investigators., Lancet 2008 Apr 19; 371:1353. Ajani AE and Lefkovits J., Lancet 2008 Apr 19; 371:1315.
Sort by:
Items 1 to 20 of 357 results - Relevance
- Date
